Pages that link to "Q33755845"

The following pages link to Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression (Q33755845):

Displaying 42 items.

• Role of cerebral cortex in the neuropathology of Huntington's disease (Q26829211) (← links)
• Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy (Q26849677) (← links)
• Mouse models of polyglutamine diseases: review and data table. Part I (Q26853025) (← links)
• Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. (Q27316866) (← links)
• Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease (Q27346849) (← links)
• Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice (Q30475466) (← links)
• The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling (Q30535295) (← links)
• A fully humanized transgenic mouse model of Huntington disease. (Q30537951) (← links)
• microRNA-128a dysregulation in transgenic Huntington's disease monkeys (Q33786296) (← links)
• Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice (Q34070946) (← links)
• Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. (Q34440282) (← links)
• Increased Body Weight of the BAC HD Transgenic Mouse Model of Huntington's Disease Accounts for Some but Not All of the Observed HD-like Motor Deficits. (Q34991104) (← links)
• IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease (Q35370058) (← links)
• Neurodegenerative processes in Huntington's disease (Q35572092) (← links)
• Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease (Q35747131) (← links)
• Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo (Q35905407) (← links)
• Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. (Q36056302) (← links)
• Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue (Q36106687) (← links)
• Cross-phenotype association tests uncover genes mediating nutrient response in Drosophila. (Q36181271) (← links)
• Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype. (Q36315067) (← links)
• Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse (Q36459384) (← links)
• Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT. (Q36763900) (← links)
• Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease (Q36813115) (← links)
• Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis (Q37165188) (← links)
• Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice. (Q37866383) (← links)
• Choosing an animal model for the study of Huntington's disease (Q38139868) (← links)
• Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models. (Q38235229) (← links)
• Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. (Q38791517) (← links)
• Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF. (Q38928777) (← links)
• Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts. (Q38993673) (← links)
• Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits (Q42486219) (← links)
• A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. (Q45290510) (← links)
• Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice (Q45293567) (← links)
• Single-cell suspension methodology favors survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington's disease. (Q45293677) (← links)
• IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. (Q45296557) (← links)
• Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. (Q45303268) (← links)
• Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice (Q45306356) (← links)
• Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders (Q46309597) (← links)
• Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. (Q49659203) (← links)
• Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease (Q51238345) (← links)
• Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntington's disease (Q60912893) (← links)
• Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: From molecular pathogenesis to therapeutic perspectives (Q89478133) (← links)